Abstract
A genetic polymorphism characterized by deficient drug oxidation exists for the hydroxylation of mephenytoin. This deficiency was first recognized in a family study that suggested an autosomal recessive pattern of inheritance. To confirm the observation, we investigated 28 relatives of five poor metabolizers. Subjects ingested 50 mg of mephenytoin, and the 24-hr urine was analyzed for hydroxymephenytoin. The pedigree data shown here provide strong evidence that deficient mephenytoin hydroxylation is an autosomal recessive trait.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Eichelbaum M., Spannbrucker N., Steincke B., Dengler H. J. Defective N-oxidation of sparteine in man: a new pharmacogenetic defect. Eur J Clin Pharmacol. 1979 Sep;16(3):183–187. doi: 10.1007/BF00562059. [DOI] [PubMed] [Google Scholar]
- Evans D. A., Mahgoub A., Sloan T. P., Idle J. R., Smith R. L. A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population. J Med Genet. 1980 Apr;17(2):102–105. doi: 10.1136/jmg.17.2.102. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Inaba T., Jurima M., Mahon W. A., Kalow W. In vitro inhibition studies of two isozymes of human liver cytochrome P-450. Mephenytoin p-hydroxylase and sparteine monooxygenase. Drug Metab Dispos. 1985 Jul-Aug;13(4):443–448. [PubMed] [Google Scholar]
- Inaba T., Jurima M., Nakano M., Kalow W. Mephenytoin and sparteine pharmacogenetics in Canadian Caucasians. Clin Pharmacol Ther. 1984 Nov;36(5):670–676. doi: 10.1038/clpt.1984.238. [DOI] [PubMed] [Google Scholar]
- Jurima M., Inaba T., Kadar D., Kalow W. Genetic polymorphism of mephenytoin p(4')-hydroxylation: difference between Orientals and Caucasians. Br J Clin Pharmacol. 1985 Apr;19(4):483–487. doi: 10.1111/j.1365-2125.1985.tb02673.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Jurima M., Inaba T., Kalow W. Sparteine oxidation by the human liver: absence of inhibition by mephenytoin. Clin Pharmacol Ther. 1984 Mar;35(3):426–428. doi: 10.1038/clpt.1984.54. [DOI] [PubMed] [Google Scholar]
- Küpfer A., Desmond P. V., Schenker S., Branch R. A. Stereoselective metabolism and disposition of the enantiomers of mephenytoin during chronic oral administration of the racemic drug in man. J Pharmacol Exp Ther. 1982 Jun;221(3):590–597. [PubMed] [Google Scholar]
- Küpfer A., Desmond P., Patwardhan R., Schenker S., Branch R. A. Mephenytoin hydroxylation deficiency: kinetics after repeated doses. Clin Pharmacol Ther. 1984 Jan;35(1):33–39. doi: 10.1038/clpt.1984.5. [DOI] [PubMed] [Google Scholar]
- Küpfer A., Preisig R. Pharmacogenetics of mephenytoin: a new drug hydroxylation polymorphism in man. Eur J Clin Pharmacol. 1984;26(6):753–759. doi: 10.1007/BF00541938. [DOI] [PubMed] [Google Scholar]
- Küpfer A., Roberts R. K., Schenker S., Branch R. A. Stereoselective metabolism of mephenytoin in man. J Pharmacol Exp Ther. 1981 Jul;218(1):193–199. [PubMed] [Google Scholar]
- Wedlund P. J., Aslanian W. S., McAllister C. B., Wilkinson G. R., Branch R. A. Mephenytoin hydroxylation deficiency in Caucasians: frequency of a new oxidative drug metabolism polymorphism. Clin Pharmacol Ther. 1984 Dec;36(6):773–780. doi: 10.1038/clpt.1984.256. [DOI] [PubMed] [Google Scholar]